EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Pragmatische Studie

Pertuzumab and Trastuzumab in Patients With ERBB2/3 -Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study

John K Chan, Michael Rothe, Elizabeth Garrett-Mayer iD, Evan Pisick, Pooja Ghatalia, Andrew Gregory iD, Mollie deShazo, Kathryn F Mileham iD, Martina C Murphy, Olatunji B Alese iD, Elie G Dib iD, Peter C Kohler und 7 weitere

JCO Precision Oncology · 2026-04 · 10 (4)

DOI: 10.1200/po-25-01250 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2026-04. Verfasst von John K Chan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Sutter Cancer Research Consortium, San Francisco, CA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Erb-b2 Receptor Tyrosine Kinases, Ovarian Neoplasms. Die Arbeit nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with urothelial (UC) or ovarian/fallopian tube cancer (OC/FTC) with ERBB2/3 alterations treated with pertuzumab plus trastuzumab (P + T) are reported. METHODS Eligible patients had advanced cancer, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with ERBB2/3 alterations, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. Simon's two-stage design is based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety. RESULTS Patients with UC (n = 28) or OC/FTC (n = 25) with ERBB2/3 alterations were enrolled from March 2017 to June 2023. In the UC cohort, the DC and OR rates were 37% (90% CI, 24 to 100) and 25% (95% CI, 11 to 45), respectively. The null hypothesis of 15% DC rate was rejected ( P = .005). In the OC/FTC cancer cohort, the DC and OR rates were 23% (90% CI, 9 to 100) and 8% (95% CI, 1 to 26), respectively. The null hypothesis of 15% DC rate was not rejected ( P = .35). Six patients had at least one grade 3-5 adverse event (AE) or serious AE at least possibly related to treatment. CONCLUSION The combination of P + T met prespecified criteria to declare a signal of activity in patients with UC with ERBB2/3 alterations, but not in patients with OC/FTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesOvarian NeoplasmsReceptor, ErbB-3TrastuzumabUrologic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRegistries

Substanzen

Antibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanERBB3 protein, humanpertuzumabReceptor, ErbB-3Trastuzumab

Autor:innen und Institutionen

  • Sutter Cancer Research Consortium, San Francisco, CA.
  • American Society of Clinical Oncology, Alexandria, VA.
  • City of Hope Chicago, Zion, IL.
  • Fox Chase Cancer Center, Philadelphia, PA.
  • Advocate Aurora Healthcare, Milwaukee, WI.
  • O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL.

ORCID-Profile: Elizabeth Garrett-Mayer, Andrew Gregory, Kathryn F Mileham, Olatunji B Alese, Elie G Dib, Justin T Moyers, Pam K Mangat, Dominique C Hinshaw, Abigail Gregory, Gina N Grantham, Susan Halabi, Richard L Schilsky

Zitieren

APA

Chan, J. K., Rothe, M., Garrett-Mayer, E., Pisick, E., Ghatalia, P., Gregory, A., deShazo, M., Mileham, K. F., Murphy, M. C., Alese, O. B., Dib, E. G., Kohler, P. C., Moyers, J. T., Mangat, P. K., Hinshaw, D. C., Gregory, A., Grantham, G. N., Halabi, S., & Schilsky, R. L. (2026). Pertuzumab and Trastuzumab in Patients With ERBB2/3 -Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 10(4). https://doi.org/10.1200/po-25-01250

Vancouver

Chan JK, Rothe M, Garrett-Mayer E, Pisick E, Ghatalia P, Gregory A, et al. Pertuzumab and Trastuzumab in Patients With ERBB2/3 -Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 2026;10(4). doi:10.1200/po-25-01250

BibTeX
@article{Chan2026,
  author = {Chan, John K and Rothe, Michael and Garrett-Mayer, Elizabeth and Pisick, Evan and Ghatalia, Pooja and Gregory, Andrew and deShazo, Mollie and Mileham, Kathryn F and Murphy, Martina C and Alese, Olatunji B and Dib, Elie G and Kohler, Peter C and Moyers, Justin T and Mangat, Pam K and Hinshaw, Dominique C and Gregory, Abigail and Grantham, Gina N and Halabi, Susan and Schilsky, Richard L},
  title = {Pertuzumab and Trastuzumab in Patients With ERBB2/3 -Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1200/po-25-01250}
}
Kostenlos starten →